Cassava Sciences : Corporate Presentation – January 2023

We Focus on Alzheimer's disease

January 2023

Forward-Looking Statements & Safe Harbor

This presentation from Cassava Sciences contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to: our strategy and plans; the size and scope of our pivotal Phase 3 trial and its likelihood of success; the interpretation of clinical data generated in our open-label study; the approximate times we expect to announce clinical results of our open-label study or CMS study; the treatment of Alzheimer's disease; the status of current and future clinical studies with simufilam, including patient enrollment goals in 2023 for our Phase 3 study; the safety or efficacy of simufilam in patients; the development path for SavaDx or the use of mass spectrometry as an alternative method of detection; expected cash use in future periods; clinical data presented at the 2021 Alzheimer's Association International Conference (AAIC), including a subsequent erratum regarding visual errors not caught in proofing; a technical paper published in 2017 in Neurobiology of Aging and a subsequent erratum regarding a visual error not caught in proofing; verbal commentaries made by our employees; and potential benefits, if any, of the our product candidates. These statements may be identified by words such as "may," "anticipate," "believe," "could,"

"expect," "forecast," "intend," "plan," "possible," "potential," and other words and terms of similar meaning.

Simufilam and SavaDx are investigational product candidates. They are not approved by any regulatory authority and their safety, efficacy or other desirable attributes have not been established in patients. All clinical data from our open-label study are inherently exploratory in nature and, as with all open-label data, should be interpreted with caution. Data results from our open-label study does not constitute, and should not be interpreted as, evidence of therapeutic safety or benefit for simufilam.

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in regulatory approval and subsequent commercialization of a product. In addition, our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. Also, our interim data and analysis should not be relied upon as predictive of full study results for the open- label study, or any other study. You should not place undue reliance on these statements or any scientific data we present or publish.

Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, potential health benefits, if any, of changes in levels of biomarkers, the severity and duration of health care precautions given the COVID-19 pandemic, any unanticipated impacts of the pandemic on our business operations, including those described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements contained in this presentation. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.

This presentation may also contain statistical data and drug information based on independent industry publications or other publicly available information. We have not independently verified the accuracy or completeness of the data contained in these publicly available sources of data and information. Accordingly, we make no representations as to the accuracy or completeness of such data or information. You are cautioned not to give undue weight to such data.

The content of this presentation is solely our responsibility and does not represent the official views of the National Institutes of Health (NIH).

2

Introduction to Cassava Sciences

We are developing a novel drug treatment for people with

Alzheimer's disease.

Our science is based on stabilizing-but not removing-a critical protein in the brain.

Our lead drug candidate is in Phase 3 clinical trials.

3

3

Cassava Sciences - Senior Management

Remi Barbier - Chairman, President & CEO

Jim Kupiec, MD - Chief Medical Officer Two FDA

drug approvals prior to Cassava Sciences.

Eric Schoen - Chief Financial Officer

Lindsay H. Burns, PhD - SVP, Neuroscience

Michael Zamloot - SVP, Technical Operations

Four FDA drug approvals prior to Cassava Sciences.

Chris Cook - SVP, General Counsel

Mike Marsman, PharmD - SVP, Regulatory Affairs

4

Alzheimer's Disease: a Significant Unmet Need

Alzheimer's is also a world-wide epidemic.

It outranks cancer, stroke and heart attack as most- feared chronic disease by retirees, according to a study.1

Cassava Sciences sees an opportunity to create value.

Signature of Alois Alzheimer, circa 1915

"Alzheimer's disease represents one of the greatest medical challenges that face this century; the condition is becoming increasingly prevalent worldwide and as yet no effective treatments have been developed for this terminal disease."

Neurologic Clinics 2016 Nov 34(4)

5

1 Source: "The Four Pillars of the New Retirement", EdwardJones, accessed on-line November 2022.

5